[Myocardial consumption of free fatty acids and carbohydrates following treatment with a new beta-blockader (1-o-methoxyphenoxy-3-isopropylamino-2-propanol HC1) D 1601].
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D050260:Carbohydrate Metabolism; D004285:Dogs; D005230:Fatty Acids, Nonesterified / Q000378:metabolism*; D006321:Heart / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism*; D010647:Phenyl Ethers / Q000494:pharmacology; D011412:Propanolamines / Q000494:pharmacology*
D000319:Adrenergic beta-Antagonists; D005230:Fatty Acids, Nonesterified; D010647:Phenyl Ethers; D011412:Propanolamines
Consumo miocardico di acidi grassi liberi e di idrati di carbonio in seguito a trattamento con un nuovo farmaco beta-bloccante (1-o-metossifenossi-3-isopropilamino-2-propanolo HC1) D 1601